Prevention of Ischemia in Aneurysmal Subarachnoid Hemorrhage Through Remote Ischemic Preconditioning

NCT07761520 — Not applicable, Not yet recruiting, 140 participants, Centre Hospitalier Universitaire de Nice

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

Remote Ischemic Preconditioning (RIPC) and Aneurysmal Subarachnoid Hemorrhage (SAH)

Registry	NCT07761520, acronym HMA
Status	Not yet recruiting
Phase	Not applicable
Study type	Interventional; randomized, parallel, masking: double, treatment
Enrollment	140 (Estimated)
Sponsor	Centre Hospitalier Universitaire de Nice (Other)
Conditions	Aneurysmal Subarachnoid Hemorrhage
Interventions	Remote Ischemic Preconditioning, Sham Ischemic Preconditioning (Procedure)
Dates	start 2026-09-01 (estimated), primary completion 2028-12-01 (estimated), completion 2029-09-01 (estimated), first posted 2026-08-12, last updated 2026-08-12

-Summary

Aneurysmal subarachnoid hemorrhage (SAH) is a severe form of stroke caused by bleeding around the brain. Despite early treatment of the initial hemorrhage, many patients develop delayed cerebral ischemia several days later, which is a major cause of neurological disability, cognitive impairment, and mortality. Current preventive and therapeutic strategies are only partially effective, highlighting the need for new treatment approaches.

This study investigates a simple, non-invasive technique called remote ischemic preconditioning (RIPC). RIPC consists of brief, repeated cycles of limb ischemia and reperfusion induced by a blood pressure cuff. RIPC is thought to activate endogenous protective mechanisms that may improve the brain's tolerance to ischemia. Although beneficial effects have been reported in experimental models and cardiovascular diseases, its clinical efficacy in aneurysmal SAH remains uncertain.

In this randomized, controlled, single-blinded, multicenter study, adult patients admitted with aneyrysmal SAH will be randomly assigned to receive RIPC or a sham procedure. The RIPC group will undergo cycles of brief lower-limb ischemia using a pressure cuff, while the sham group will receive an identical procedure without inducing ischemia. Patients and neurologists assessing outcomes will remain blinded to group allocation.

The intervention will be performed every two days from day 2 to day 10 after hemorrhage. Neurological outcome will be assessed at 3 months using the modified Rankin Scale. Secondary outcomes include mortality at 3 months, long-term neurological and cognitive function outcomes at 12 months, and the incidence of adverse events related to the procedure.

If effective, RIPC could become a simple, low-cost, widely accessible method to reduce disability after SAH. The results may help improve future treatment strategies for this severe condition.

Expand all sections · Collapse all

+Arms and interventions

Arm	Type	Interventions	Description
Ischemic Preconditioning (RIPC)	Experimental	Procedure: Remote Ischemic Preconditioning
Sham Procedure	Placebo comparator	Procedure: Sham Ischemic Preconditioning

Remote Ischemic Preconditioning (Procedure): Three cycles of lower-limb ischemia and reperfusion using a blood pressure cuff inflated to 20 mmHg above systolic blood pressure for 5 minutes followed by 5 minutes of reperfusion. The procedure is performed every two days from day 2 to day 10 after aneurysmal subarachnoid hemorrhage.
Sham Ischemic Preconditioning (Procedure): Identical procedure to the experimental arm, except the cuff is inflated to only 30 mmHg, insufficient to induce ischemia, giving the sensation of pressure without therapeutic effect. Performed every two days from day 2 to day 10 post-hemorrhage.

+Outcome measures

Primary outcomes

Neurological Functional Outcome at 3 Months (mRS) [3 months (+/- 15 days) post-aneurysmal subarachnoid hemorrhage]: Assessment of neurological disability and dependency using the modified Rankin Scale (mRS) performed by a blinded neurologist. The mRS is a 6-point scale (0 to 5), with 5 being a severe disability.

Secondary outcomes

Evaluation of mortality at 3 Months [From day 0 to 3 months post-hemorrhage]: Comparison of all-cause mortality between the RIPC group and the sham group
Long-term Neurological Outcome at 12 Months (mRS) [12 months (+/- 30 days) post-aneurysmal subarachnoid hemorrhage]: Assessment of long-term neurological disability and dependency using the modified Rankin Scale (mRS) performed by a blinded neurologist. The mRS is a 6-point scale (0 to 5), with 5 being a severe disability.
Evaluation of Cognitive Function at 12 months (MMSE) [12 months (+/- 30 days) post-aneurysmal subarachnoid hemorrhage]: Evaluation of cognitive performance assessed using the Mini-Mental State Examination (MMSE). The MMSE score ranks from 0 to 30, with 30 being a normal congnitive performance and 0 serious cognitive impairments.
Evaluation of Cognitive Function at 12 months (MoCA) [12 months (+/- 30 days) post-aneurysmal subarachnoid hemorrhage]: Evaluation of cognitive performance assessed using the Montreal Cognitive Assessment (MoCA). The MoCA is scored out of 30 points, with high scores suggesting mild or no cognitive impairments, and low scores severe cognitive impairments.
Safety Outcomes [From day 0 until 12 months post-aneurysmal subarachnoid hemorrhage.]: Incidence, nature, and severity of adverse events and serious adverse events occurring during the study period.

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Age over 18 years
* Hospitalization for aneurysmal subarachnoid hemorrhage confirmed by CT scan and/or lumbar puncture
* Confirmation of intracranial aneurysm by CT angiography and/or cerebral angiography
* Written informed consent obtained from the patient or legal representative
* Affiliation to a social security system

Exclusion Criteria:

* Skin, orthopedic, or vascular conditions of the limbs contraindicating ischemic preconditioning (e.g., ulcers, fractures, deep vein thrombosis)
* Pregnancy
* Withdrawal of informed consent